TGen-HonorHealth Research Institute clinical trial reports high rate of tumor shrinkage
Adding cisplatin to the standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the TGen. April 25, 2017